Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
PARSIPPANY, N.J., Feb. 16, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2018 RBC Capital Markets Healthcare Conference at 9:30 AM ET on Wednesday, February 21, 2018 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
